Citation

Von Schéele B, Mauskopf J, Brodtkorb TH, Ainsworth C, Berardo CG, Patel A. Expert Rev. Pharmacoecon. Outcomes Res. 2014; 14(2): 235-257.

Copyright

(Copyright © 2014, Expert Reviews)

DOI

10.1586/14737167.2014.891443

PMID

unavailable

Abstract

Complex modeling techniques such as discrete-event simulation and simpler Markov or decision-tree models have been used to estimate the cost-effectiveness of treatment for chronic diseases such as schizophrenia. A systematic literature review of MEDLINE, EconLit, Embase, and the Cochrane Library identified schizophrenia modeling studies presenting incremental cost-effectiveness ratios. The relationship between modeling technique used and reported outcomes was examined. Fifty-four studies reporting results of 69 pairs of drug comparisons were identified. Of the paired-drug comparisons, 27 were conducted in at least two studies; in 14 of the 27, the results agreed (i.e., drug A cost-effective compared with drug B) despite differences in modeling techniques. Thirteen of the 27 paired-drug comparisons had contradictory study results even when the same modeling technique was used. Different modeling techniques did not appear to explain different findings about cost-effectiveness. © 2014 Informa UK Ltd.

Language: en

Keywords

Humans; human; systematic review; Review; Cost-Benefit Analysis; Schizophrenia; schizophrenia; quality control; suicide attempt; risk assessment; Benzodiazepines; risk factor; review; disease association; neuroleptic agent; sexual dysfunction; orthostatic hypotension; drug safety; benzodiazepine derivative; seizure; patient compliance; drug efficacy; extrapyramidal symptom; olanzapine; risperidone; tardive dyskinesia; drug tolerability; agranulocytosis; cost effectiveness analysis; negative syndrome; drug withdrawal; hyperprolactinemia; akathisia; high risk patient; neurologic disease; relapse; cost benefit analysis; diabetes mellitus; positive syndrome; dystonia; galactorrhea; hyperlipidemia; parkinsonism; hematologic disease; medical information; drug response; Economic; Risperidone; quality adjusted life year; Models; statistical model; Antipsychotic Agents; anticholinergic syndrome; neuroleptic malignant syndrome; outcome assessment; clinical effectiveness; Outcome Assessment (Health Care); mathematical model; cost minimization analysis; oligomenorrhea; Models, Economic; cost utility analysis; Antipsychotic agents; prolactinoma